Table 1.
Parameter | N | Value |
---|---|---|
Demographics | ||
Female gender | 85 | 70 (82) |
Age, years | 85 | 64.9±12.2 |
Ever/never smoker | 85 | 30 (35)/55 (65) |
Disease characteristics | ||
Limited/diffuse cutaneous SSc | 85 | 74 (87)/11 (13) |
Antinuclear antibodies | 83 | 54 (65) |
ACA positive | 83 | 33 (40) |
ATA positive | 83 | 3 (4) |
Functional capacity | ||
NYHA FC, I/II/III/IV | 82 | 0 (0)/17 (21)/55 (67)/10 (12) |
6MWD, m | 75 | 259±126 |
Echocardiography | ||
Pericardial effusion present | 55 | 14 (25) |
Pulmonary function tests | ||
FVC, % predicted | 73 | 92±21 |
TLC, % predicted | 73 | 94±15 |
FEV1, % predicted | 72 | 90±22 |
KCO, % predicted | 64 | 53±20 |
Blood gases | ||
PaO2, mm Hg | 57 | 70±18 |
PaCO2, mm Hg | 54 | 33±9 |
SaO2, % | ||
Before 6MWT | 64 | 95±3 |
Post 6MWT | 60 | 88±5 |
Blood analysis | ||
BNP, ng/l | 48 | 463±573 |
Haemodynamics | ||
RAP, mm Hg | 84 | 7±5 |
mPAP, mm Hg | 85 | 41±11 |
PCWP, mm Hg | 85 | 8±4 |
Cardiac output, l/min | 85 | 4.44±1.56 |
Cardiac index, l/min/m2 | 83 | 2.64±0.78 |
PVR, dyn/sec/cm−5 | 85 | 680±355 |
SV, ml | 71 | 57±26 |
SV/PP, ml/mm Hg | 70 | 1.81±1.59 |
RVSWI, g.m/m2 | 68 | 14.81±5.22 |
Heart rate, bpm | 71 | 83±15 |
Data are mean±SD or n (%).
6MWD/T, six-min walking distance/test; ACA, anticentromere antibody; ATA, antitopoisomerase I antibody; BNP, brain natriuretic peptide; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; KCO, diffusing capacity for carbon monoxide corrected for alveolar volume; mPAP, mean pulmonary arterial pressure; NYHA FC, New York Heart Association functional class; PAH, pulmonary arterial hypertension; PaO2/PaCO2 partial pressure of oxygen/carbon dioxide in arterial blood; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricle stroke work index; SaO2, oxygen saturation measured by pulse oximetry; SSc, systemic sclerosis; SV, stroke volume; SV/PP, pulmonary artery capacitance; TLC, total lung capacity.